Q2 2018 13F Holders as of 6/30/2018
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
58.9M
-
Number of holders
-
134
-
Total 13F shares, excl. options
-
49M
-
Shares change
-
+827K
-
Total reported value, excl. options
-
$934M
-
Value change
-
+$18.6M
-
Put/Call ratio
-
0.84
-
Number of buys
-
69
-
Number of sells
-
-54
-
Price
-
$19.05
Significant Holders of Vanda Pharmaceuticals Inc. - Common Stock, par value $0.001 per share (VNDA) as of Q2 2018
156 filings reported holding VNDA - Vanda Pharmaceuticals Inc. - Common Stock, par value $0.001 per share as of Q2 2018.
Vanda Pharmaceuticals Inc. - Common Stock, par value $0.001 per share (VNDA) has 134 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 49M shares
of 58.9M outstanding shares and own 83.27% of the company stock.
Largest 10 shareholders include BlackRock Inc. (4.96M shares), Consonance Capital Management LP (4.61M shares), Palo Alto Investors LP (4.16M shares), VANGUARD GROUP INC (3.34M shares), venBio Select Advisor LLC (2.8M shares), MACQUARIE GROUP LTD (2.56M shares), ARMISTICE CAPITAL, LLC (2.22M shares), STATE STREET CORP (2.17M shares), RENAISSANCE TECHNOLOGIES LLC (1.68M shares), and ADAGE CAPITAL PARTNERS GP, L.L.C. (1.4M shares).
This table shows the top 134 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.